<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480857</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2006.066</org_study_id>
    <secondary_id>HUM 7093</secondary_id>
    <nct_id>NCT00480857</nct_id>
  </id_info>
  <brief_title>Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy</brief_title>
  <official_title>Salvage Radiation Therapy and Docetaxel (Taxotere) for Biochemical Failure After Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to try to find out whether adding chemotherapy to the&#xD;
      standard treatment for your stage of prostate cancer is more effective than the standard&#xD;
      treatment by itself. The kind of treatment that most physicians would consider standard for&#xD;
      this stage of prostate cancer is radiation therapy alone, possibly in combination with&#xD;
      hormonal therapy. In this study, all patients will receive chemotherapy and radiation&#xD;
      therapy. It is hoped that chemotherapy will be found to provide additional benefit, but&#xD;
      chemotherapy has significant side effects. The use of chemotherapy is experimental in&#xD;
      prostate cancer; it needs to be tested to determine if it is beneficial and to find out more&#xD;
      about the side effects of the two different treatments. This study is to determine the&#xD;
      effects, good and/or bad, of adding chemotherapy to radiation therapy as &quot;salvage&quot; treatment&#xD;
      for recurrent prostate cancer after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no treatment proven more effective for clinically localized prostate cancer than&#xD;
      radical prostatectomy. Nonetheless, approximately 30,000 men annually in the U.S. develop&#xD;
      recurrence of their prostate cancer after prostatectomy. Radiation therapy is commonly&#xD;
      utilized as attempted salvage treatment for patients who develop a rising PSA (Prostate&#xD;
      Specific Antigen) after prostatectomy and have no evidence of metastatic disease. This study&#xD;
      is designed to determine whether concurrent chemotherapy, weekly docetaxel, and daily&#xD;
      radiation therapy will result in improved disease control and survival rates over those&#xD;
      obtained with radiotherapy alone in the treatment of men with biochemical recurrence after&#xD;
      radical prostatectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding.&#xD;
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Alive Without Progression at 4 Years</measure>
    <time_frame>4 years</time_frame>
    <description>The primary objective is to assess the 4-year progression free proportion of patients treated with concurrent weekly docetaxel (TAXOTERE) and salvage prostate bed radiation therapy among patients with biochemical recurrence after radical prostatectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Achieve a Post-radiotherapy PSA Nadir of 0.1 ng/mL or Less</measure>
    <time_frame>4 years</time_frame>
    <description>To determine the rates of complete biochemical response (as defined by achievement of a post-radiotherapy PSA nadir of 0.1 ng/mL or less) after concurrent weekly docetaxel (TAXOTERE) and salvage prostate bed radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients That Experience at Least 1 Grade 1, 2, 3 and 4 Toxicities</measure>
    <time_frame>4 years</time_frame>
    <description>To determine the rates of toxicities among patients treated with concurrent weekly docetaxel (TAXOTERE) and salvage prostate bed radiation therapy.&#xD;
G1 events are considered mild. G2 events are considered moderate G3 events are considered severe G4 events are considered life-threatening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients That Experience Evidence of Local Recurrence</measure>
    <time_frame>4 years</time_frame>
    <description>The number of patients that have local disease recurrence by imaging and clinical findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients Alive</measure>
    <time_frame>4 years</time_frame>
    <description>The number of patients alive at 4 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel (Taxotere)</intervention_name>
    <description>Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Performance Status: Karnofsky performance status ≥ 80% (Performance status is an&#xD;
             attempt to quantify cancer patients' general well-being and activities of daily life.&#xD;
             The Karnofsky score runs from 100 to 0, where 100 is &quot;perfect&quot; health and 0 is death.)&#xD;
&#xD;
          -  Has undergone prostatectomy for histologically confirmed adenocarcinoma of the&#xD;
             prostate at least 6 weeks prior to registration. (If prostatectomy was completed at an&#xD;
             outside facility, a University of Michigan pathology review must take place to confirm&#xD;
             adenocarcinoma.)&#xD;
&#xD;
          -  Has biochemical evidence of failure as determined by at least two PSA measurements&#xD;
             after prostatectomy. This must be demonstrated by an increase of at least 0.1 ng/mL&#xD;
             between two consecutive measurements, both obtained after prostatectomy. The most&#xD;
             recent measurement (within 28 days of registration) must be 0.3 ng/mL or greater.&#xD;
&#xD;
          -  Has undergone pelvic CT (Computerized Tomography) scan and radionuclide bone scan&#xD;
             within 90 days prior to registration that showed no evidence of regional or distant&#xD;
             nodal or bone metastasis.&#xD;
&#xD;
          -  Patients with pelvic or abdominal lymph nodes equivocal or questionable by imaging are&#xD;
             eligible if the nodes are &lt; 1.5 cm in long axis.&#xD;
&#xD;
          -  Equivocal bone scan findings are allowed if plain films show no conclusive evidence of&#xD;
             metastasis.&#xD;
&#xD;
          -  Hematologic Criteria: CBC (Complete Blood Count)/differential obtained within 28 days&#xD;
             prior to registration on study, with adequate bone marrow function defined as follows:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3&#xD;
&#xD;
               -  Platelets ≥ 100,000 cells/mm3&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to&#xD;
                  achieve Hgb = 8.0 g/dl is acceptable).&#xD;
&#xD;
          -  Hepatic Criteria within 28 days prior to registration:&#xD;
&#xD;
               -  Total bilirubin &lt; 1 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  ALT (Alanine Transaminase), AST (Aspartate Aminotransferase), and alkaline&#xD;
                  phosphatase must be within the eligible ranges stipulated in protocol table&#xD;
&#xD;
               -  Serum creatinine &lt; 2 x ULN&#xD;
&#xD;
          -  Both radiation oncology and medical oncology consultation prior to registration.&#xD;
&#xD;
          -  Pharmacologic androgen ablation for prostate cancer will be allowed only if given&#xD;
             prior to prostatectomy.&#xD;
&#xD;
          -  Patient must sign study specific informed consent prior to study entry.&#xD;
&#xD;
          -  Peripheral neuropathy: must be ≤ grade 1&#xD;
&#xD;
          -  Patients must be willing to consent to using effective contraception while on&#xD;
             treatment and for at least 3 months thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of severe hypersensitivity reaction to docetaxel or other&#xD;
             drugs formulated with polysorbate 80.&#xD;
&#xD;
          -  Evidence of M1 metastatic disease&#xD;
&#xD;
          -  Pathologically positive lymph nodes or nodes &gt; 1.5 cm on imaging&#xD;
&#xD;
          -  Prior pelvic radiotherapy that would result in overlap of radiation therapy fields or&#xD;
             systemic cytotoxic chemotherapy.&#xD;
&#xD;
          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free&#xD;
             for a minimum of 5 years (for example,carcinoma in situ of the oral cavity or bladder&#xD;
             are permissible)&#xD;
&#xD;
          -  Severe, active co-morbidity, defined as follows, active co-morbidity, defined as&#xD;
             follows:&#xD;
&#xD;
               -  Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the 6 months prior to registration.&#xD;
&#xD;
               -  Transmural myocardial infarction within the 6 months prior to registration&#xD;
&#xD;
               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time&#xD;
                  of registration&#xD;
&#xD;
               -  Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition;&#xD;
                  note, however, that HIV testing is not required for entry into this protocol. The&#xD;
                  need to exclude patients with AIDS from this protocol is necessary because the&#xD;
                  treatments involved in this protocol may be significantly immunosuppressive.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel A. Hamstra, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jackson WC, Feng FY, Daignault S, Hussain M, Smith D, Cooney K, Pienta K, Jolly S, Hollenbeck B, Olson KB, Sandler HM, Ray ME, Hamstra DA. A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. Adv Radiat Oncol. 2015 Dec 9;1(1):59-66. doi: 10.1016/j.adro.2015.11.001. eCollection 2016 Jan-Mar.</citation>
    <PMID>28799570</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 29, 2007</study_first_submitted>
  <study_first_submitted_qc>May 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2007</study_first_posted>
  <results_first_submitted>January 9, 2015</results_first_submitted>
  <results_first_submitted_qc>January 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2015</results_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel</title>
          <description>Docetaxel (Taxotere): Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel</title>
          <description>Docetaxel (Taxotere): Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="43" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Alive Without Progression at 4 Years</title>
        <description>The primary objective is to assess the 4-year progression free proportion of patients treated with concurrent weekly docetaxel (TAXOTERE) and salvage prostate bed radiation therapy among patients with biochemical recurrence after radical prostatectomy.</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel</title>
            <description>Docetaxel (Taxotere): Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Alive Without Progression at 4 Years</title>
          <description>The primary objective is to assess the 4-year progression free proportion of patients treated with concurrent weekly docetaxel (TAXOTERE) and salvage prostate bed radiation therapy among patients with biochemical recurrence after radical prostatectomy.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="24" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Achieve a Post-radiotherapy PSA Nadir of 0.1 ng/mL or Less</title>
        <description>To determine the rates of complete biochemical response (as defined by achievement of a post-radiotherapy PSA nadir of 0.1 ng/mL or less) after concurrent weekly docetaxel (TAXOTERE) and salvage prostate bed radiation therapy.</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel</title>
            <description>Docetaxel (Taxotere): Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Achieve a Post-radiotherapy PSA Nadir of 0.1 ng/mL or Less</title>
          <description>To determine the rates of complete biochemical response (as defined by achievement of a post-radiotherapy PSA nadir of 0.1 ng/mL or less) after concurrent weekly docetaxel (TAXOTERE) and salvage prostate bed radiation therapy.</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients That Experience at Least 1 Grade 1, 2, 3 and 4 Toxicities</title>
        <description>To determine the rates of toxicities among patients treated with concurrent weekly docetaxel (TAXOTERE) and salvage prostate bed radiation therapy.&#xD;
G1 events are considered mild. G2 events are considered moderate G3 events are considered severe G4 events are considered life-threatening</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel</title>
            <description>Docetaxel (Taxotere): Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients That Experience at Least 1 Grade 1, 2, 3 and 4 Toxicities</title>
          <description>To determine the rates of toxicities among patients treated with concurrent weekly docetaxel (TAXOTERE) and salvage prostate bed radiation therapy.&#xD;
G1 events are considered mild. G2 events are considered moderate G3 events are considered severe G4 events are considered life-threatening</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients that experience at least 1 G1 toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients that experience at least 1 G2 toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients that experience at least 1 G3 toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients that experience at least 1 G4 toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients That Experience Evidence of Local Recurrence</title>
        <description>The number of patients that have local disease recurrence by imaging and clinical findings.</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel</title>
            <description>Docetaxel (Taxotere): Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients That Experience Evidence of Local Recurrence</title>
          <description>The number of patients that have local disease recurrence by imaging and clinical findings.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients Alive</title>
        <description>The number of patients alive at 4 years.</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel</title>
            <description>Docetaxel (Taxotere): Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients Alive</title>
          <description>The number of patients alive at 4 years.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel</title>
          <description>Docetaxel (Taxotere): Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Gastrointestinal Bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Frequency/Urgency</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rectal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper GI Bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Weights Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Frequency/Urgency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Hamstra</name_or_title>
      <organization>University of Michigan Comprehensive Cancer Center</organization>
      <phone>(734) 936-4300</phone>
      <email>dhamm@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

